Skip Content
Page Banner Image


Triplet Therapeutics has developed the SHIELD HD natural history study for Huntington disease (HD), which recently enrolled its first patients. The study will include about 60 HD gene carriers – both pre-manifest and early manifest individuals – and is intended to inform future clinical trials.

If you’re not familiar with Triplet’s therapeutic approach, it’s different from other therapies currently entering the HD clinic, in that it targets a newly discovered set of modifiers for HD instead of the HTT gene. Operating “upstream” means that Triplet may be able to treat the disease very early — an approach that could preserve neuronal function and halt neurodegeneration.

The study is registered at and you can view the full HSG webpage regarding the study online here.

Status: Currently recruiting.

Study Type: Phase III Clinical Trial

Canadian Locations:

British Columbia

Location: Neurocrine Clinical Site, UBC
Vancouver, BC  V6T 2B5

If you are interested in participating in KINECT-HD, please contact the HSG to be connected to a site nearest to you. Study center personnel will determine your eligibility to participate in the KINECT-HD study.

Call Toll-Free (North America): 800-487-7671

We support those facing huntington disease
 Latest Blog


Let Us Know How We Can Help
Enter your name, email address and question(s) below for assistance.



Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up